ROX Medical, Inc. (ROX), a privately held medical device company pioneering a minimally-invasive therapy for hypertension, today announced the appointment of Mike MacKinnon as its Chief Executive Officer.
“Despite the many classes of drugs available to physicians to treat hypertension, millions of patients still have blood pressures that are uncontrolled or resistant to treatment, leading to serious conditions including stroke, heart attack, heart failure and kidney disease,” said Mr. MacKinnon. “By diverting blood from the arteries to the veins via a small stent in a short, outpatient procedure, the impact of the ROX Coupler device on blood pressure has been shown to be long-lasting and immediate. I am excited to work with the physician-investigators on the FDA-approved US pivotal study to build the evidence for this potentially life-saving technology.”
Mr. MacKinnon joins ROX from Philips North America where he was Head of Sales for Image Guided Technologies, Devices. He joined Philips through the acquisition of Volcano where he was General Manager of Phoenix Atherectomy and Peripheral Sales Leader. In 2014, Volcano acquired AtheroMed where Mike was President and CEO. Prior to AtheroMed, Mr. MacKinnon held various leadership positions with Hansen Medical, Access Closure and FoxHollow Technologies.
“Mike is a seasoned medical device executive whose expertise lies in commercializing game-changing cardiovascular technologies,” commented Board Member David McIntyre. “We are thrilled to bring Mike’s leadership and energy to the ROX team as this technology progresses to the market and potentially becomes the standard of care in hypertension.”